Loading…
Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma
OBJECTIVE To evaluate the clinical utility of lung radiofrequency ablation (RFA) in patients with unresectable pulmonary metastasis from renal cell carcinoma (RCC). PATIENTS AND METHODS We retrospectively examined 39 patients with unresectable metastases from RCC who were treated with lung RFA. Pati...
Saved in:
| Published in: | BJU international 2009-09, Vol.104 (6), p.790-794 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4639-7b53f75ba3effd7bbb21a3f2c12abf920d1d51f7bfa867c69352ef27b2ec4a823 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4639-7b53f75ba3effd7bbb21a3f2c12abf920d1d51f7bfa867c69352ef27b2ec4a823 |
| container_end_page | 794 |
| container_issue | 6 |
| container_start_page | 790 |
| container_title | BJU international |
| container_volume | 104 |
| creator | Soga, Norihito Yamakado, Koichiro Gohara, Hideo Takaki, Haruyuki Hiraki, Takao Yamada, Tomomi Arima, Kiminobu Takeda, Kan Kanazawa, Susumu Sugimura, Yoshiki |
| description | OBJECTIVE
To evaluate the clinical utility of lung radiofrequency ablation (RFA) in patients with unresectable pulmonary metastasis from renal cell carcinoma (RCC).
PATIENTS AND METHODS
We retrospectively examined 39 patients with unresectable metastases from RCC who were treated with lung RFA. Patients with six or fewer lung metastases measuring ≤6 cm that were confined in the lung, had all lung tumours ablated (curative ablation). Patients with extrapulmonary lesions, seven or more lung tumours, or large tumours of >6 cm, had mass reduction (palliative ablation). The primary endpoints was the overall survival, secondary endpoints were safety, local tumour progression rate, and recurrence‐free survival in the curative ablation group.
RESULTS
There were significant differences in the overall survival rates between the curative and palliative groups at 1 year (100% vs 90%), 3 years (100% vs 52%) and 5 years (100% vs 52%) (P |
| doi_str_mv | 10.1111/j.1464-410X.2009.08459.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67608020</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67608020</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4639-7b53f75ba3effd7bbb21a3f2c12abf920d1d51f7bfa867c69352ef27b2ec4a823</originalsourceid><addsrcrecordid>eNqNkMlO5DAQhi00iP0VkC8ztw5e4iwHDjOIVUhwAImbVXbKUlpJ3NiJoN8eh26YK5blKpW_suv_CaGcZTyts2XG8yJf5Jy9ZIKxOmNVrursfYccfF_8-spZXeyTwxiXjKVCofbIPq-lrJRSB6R5xGCnEQb0U6QBmta7gK8TDnZNwXQwtn6gzgc6DQEj2jEVka6mrvcDhDXtcYSYNkbqgu9pwAE6arFLBwTbDr6HY7LroIt4so1H5Pnq8uniZnH_cH178fd-YfNC1ovSKOlKZUCic01pjBEcpBOWCzCuFqzhjeKuNA6qorRFLZVAJ0oj0OZQCXlE_mzeXQWfJMRR922cR9nI00VZsIoJlsBqA9rgYwzo9Cq0fZKjOdOzw3qpZ_P0bKSeHdafDuv31Hq6_WMyPTb_G7eWJuD3FoBooXMBBtvGb07wSkle54k733BvbYfrHw-g_909z5n8AF7Pmq4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67608020</pqid></control><display><type>article</type><title>Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Soga, Norihito ; Yamakado, Koichiro ; Gohara, Hideo ; Takaki, Haruyuki ; Hiraki, Takao ; Yamada, Tomomi ; Arima, Kiminobu ; Takeda, Kan ; Kanazawa, Susumu ; Sugimura, Yoshiki</creator><creatorcontrib>Soga, Norihito ; Yamakado, Koichiro ; Gohara, Hideo ; Takaki, Haruyuki ; Hiraki, Takao ; Yamada, Tomomi ; Arima, Kiminobu ; Takeda, Kan ; Kanazawa, Susumu ; Sugimura, Yoshiki</creatorcontrib><description>OBJECTIVE
To evaluate the clinical utility of lung radiofrequency ablation (RFA) in patients with unresectable pulmonary metastasis from renal cell carcinoma (RCC).
PATIENTS AND METHODS
We retrospectively examined 39 patients with unresectable metastases from RCC who were treated with lung RFA. Patients with six or fewer lung metastases measuring ≤6 cm that were confined in the lung, had all lung tumours ablated (curative ablation). Patients with extrapulmonary lesions, seven or more lung tumours, or large tumours of >6 cm, had mass reduction (palliative ablation). The primary endpoints was the overall survival, secondary endpoints were safety, local tumour progression rate, and recurrence‐free survival in the curative ablation group.
RESULTS
There were significant differences in the overall survival rates between the curative and palliative groups at 1 year (100% vs 90%), 3 years (100% vs 52%) and 5 years (100% vs 52%) (P < 0.05). The maximum lung tumour diameter was also a significant prognostic factor. There was local tumour progression in 13 patients (33%) during the mean follow‐up of 25 months. The recurrence‐free survival rates were 92% at 1 year, 23% at 3 years and 23% at 5 years in the curative ablation group. Pneumothorax requiring chest tube placement (six of 89, 7%) and pneumonia (one of 89, 1%) were major complications.
CONCLUSION
Lung RFA is a safe and effective treatment for prolonging survival in patients with unresectable RCC lung metastases.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/j.1464-410X.2009.08459.x</identifier><identifier>PMID: 19338555</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Carcinoma, Renal Cell - mortality ; Carcinoma, Renal Cell - secondary ; Carcinoma, Renal Cell - surgery ; Catheter Ablation - adverse effects ; Catheter Ablation - methods ; Diseases of the respiratory system ; Female ; Humans ; Kidney Neoplasms ; Kidneys ; lung metastasis ; Lung Neoplasms - mortality ; Lung Neoplasms - secondary ; Lung Neoplasms - surgery ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Palliative Care ; percutaneous radiofrequency ablation ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; renal cell carcinoma ; Retrospective Studies ; Survival Rate ; Treatment Outcome ; Tumors of the urinary system</subject><ispartof>BJU international, 2009-09, Vol.104 (6), p.790-794</ispartof><rights>2009 THE AUTHORS. JOURNAL COMPILATION © 2009 BJU INTERNATIONAL</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4639-7b53f75ba3effd7bbb21a3f2c12abf920d1d51f7bfa867c69352ef27b2ec4a823</citedby><cites>FETCH-LOGICAL-c4639-7b53f75ba3effd7bbb21a3f2c12abf920d1d51f7bfa867c69352ef27b2ec4a823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21853194$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19338555$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Soga, Norihito</creatorcontrib><creatorcontrib>Yamakado, Koichiro</creatorcontrib><creatorcontrib>Gohara, Hideo</creatorcontrib><creatorcontrib>Takaki, Haruyuki</creatorcontrib><creatorcontrib>Hiraki, Takao</creatorcontrib><creatorcontrib>Yamada, Tomomi</creatorcontrib><creatorcontrib>Arima, Kiminobu</creatorcontrib><creatorcontrib>Takeda, Kan</creatorcontrib><creatorcontrib>Kanazawa, Susumu</creatorcontrib><creatorcontrib>Sugimura, Yoshiki</creatorcontrib><title>Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>OBJECTIVE
To evaluate the clinical utility of lung radiofrequency ablation (RFA) in patients with unresectable pulmonary metastasis from renal cell carcinoma (RCC).
PATIENTS AND METHODS
We retrospectively examined 39 patients with unresectable metastases from RCC who were treated with lung RFA. Patients with six or fewer lung metastases measuring ≤6 cm that were confined in the lung, had all lung tumours ablated (curative ablation). Patients with extrapulmonary lesions, seven or more lung tumours, or large tumours of >6 cm, had mass reduction (palliative ablation). The primary endpoints was the overall survival, secondary endpoints were safety, local tumour progression rate, and recurrence‐free survival in the curative ablation group.
RESULTS
There were significant differences in the overall survival rates between the curative and palliative groups at 1 year (100% vs 90%), 3 years (100% vs 52%) and 5 years (100% vs 52%) (P < 0.05). The maximum lung tumour diameter was also a significant prognostic factor. There was local tumour progression in 13 patients (33%) during the mean follow‐up of 25 months. The recurrence‐free survival rates were 92% at 1 year, 23% at 3 years and 23% at 5 years in the curative ablation group. Pneumothorax requiring chest tube placement (six of 89, 7%) and pneumonia (one of 89, 1%) were major complications.
CONCLUSION
Lung RFA is a safe and effective treatment for prolonging survival in patients with unresectable RCC lung metastases.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Renal Cell - mortality</subject><subject>Carcinoma, Renal Cell - secondary</subject><subject>Carcinoma, Renal Cell - surgery</subject><subject>Catheter Ablation - adverse effects</subject><subject>Catheter Ablation - methods</subject><subject>Diseases of the respiratory system</subject><subject>Female</subject><subject>Humans</subject><subject>Kidney Neoplasms</subject><subject>Kidneys</subject><subject>lung metastasis</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - secondary</subject><subject>Lung Neoplasms - surgery</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Palliative Care</subject><subject>percutaneous radiofrequency ablation</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>renal cell carcinoma</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Tumors of the urinary system</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqNkMlO5DAQhi00iP0VkC8ztw5e4iwHDjOIVUhwAImbVXbKUlpJ3NiJoN8eh26YK5blKpW_suv_CaGcZTyts2XG8yJf5Jy9ZIKxOmNVrursfYccfF_8-spZXeyTwxiXjKVCofbIPq-lrJRSB6R5xGCnEQb0U6QBmta7gK8TDnZNwXQwtn6gzgc6DQEj2jEVka6mrvcDhDXtcYSYNkbqgu9pwAE6arFLBwTbDr6HY7LroIt4so1H5Pnq8uniZnH_cH178fd-YfNC1ovSKOlKZUCic01pjBEcpBOWCzCuFqzhjeKuNA6qorRFLZVAJ0oj0OZQCXlE_mzeXQWfJMRR922cR9nI00VZsIoJlsBqA9rgYwzo9Cq0fZKjOdOzw3qpZ_P0bKSeHdafDuv31Hq6_WMyPTb_G7eWJuD3FoBooXMBBtvGb07wSkle54k733BvbYfrHw-g_909z5n8AF7Pmq4</recordid><startdate>200909</startdate><enddate>200909</enddate><creator>Soga, Norihito</creator><creator>Yamakado, Koichiro</creator><creator>Gohara, Hideo</creator><creator>Takaki, Haruyuki</creator><creator>Hiraki, Takao</creator><creator>Yamada, Tomomi</creator><creator>Arima, Kiminobu</creator><creator>Takeda, Kan</creator><creator>Kanazawa, Susumu</creator><creator>Sugimura, Yoshiki</creator><general>Blackwell Publishing Ltd</general><general>Wiley-Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200909</creationdate><title>Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma</title><author>Soga, Norihito ; Yamakado, Koichiro ; Gohara, Hideo ; Takaki, Haruyuki ; Hiraki, Takao ; Yamada, Tomomi ; Arima, Kiminobu ; Takeda, Kan ; Kanazawa, Susumu ; Sugimura, Yoshiki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4639-7b53f75ba3effd7bbb21a3f2c12abf920d1d51f7bfa867c69352ef27b2ec4a823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Renal Cell - mortality</topic><topic>Carcinoma, Renal Cell - secondary</topic><topic>Carcinoma, Renal Cell - surgery</topic><topic>Catheter Ablation - adverse effects</topic><topic>Catheter Ablation - methods</topic><topic>Diseases of the respiratory system</topic><topic>Female</topic><topic>Humans</topic><topic>Kidney Neoplasms</topic><topic>Kidneys</topic><topic>lung metastasis</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - secondary</topic><topic>Lung Neoplasms - surgery</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Palliative Care</topic><topic>percutaneous radiofrequency ablation</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>renal cell carcinoma</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Tumors of the urinary system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soga, Norihito</creatorcontrib><creatorcontrib>Yamakado, Koichiro</creatorcontrib><creatorcontrib>Gohara, Hideo</creatorcontrib><creatorcontrib>Takaki, Haruyuki</creatorcontrib><creatorcontrib>Hiraki, Takao</creatorcontrib><creatorcontrib>Yamada, Tomomi</creatorcontrib><creatorcontrib>Arima, Kiminobu</creatorcontrib><creatorcontrib>Takeda, Kan</creatorcontrib><creatorcontrib>Kanazawa, Susumu</creatorcontrib><creatorcontrib>Sugimura, Yoshiki</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soga, Norihito</au><au>Yamakado, Koichiro</au><au>Gohara, Hideo</au><au>Takaki, Haruyuki</au><au>Hiraki, Takao</au><au>Yamada, Tomomi</au><au>Arima, Kiminobu</au><au>Takeda, Kan</au><au>Kanazawa, Susumu</au><au>Sugimura, Yoshiki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2009-09</date><risdate>2009</risdate><volume>104</volume><issue>6</issue><spage>790</spage><epage>794</epage><pages>790-794</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><abstract>OBJECTIVE
To evaluate the clinical utility of lung radiofrequency ablation (RFA) in patients with unresectable pulmonary metastasis from renal cell carcinoma (RCC).
PATIENTS AND METHODS
We retrospectively examined 39 patients with unresectable metastases from RCC who were treated with lung RFA. Patients with six or fewer lung metastases measuring ≤6 cm that were confined in the lung, had all lung tumours ablated (curative ablation). Patients with extrapulmonary lesions, seven or more lung tumours, or large tumours of >6 cm, had mass reduction (palliative ablation). The primary endpoints was the overall survival, secondary endpoints were safety, local tumour progression rate, and recurrence‐free survival in the curative ablation group.
RESULTS
There were significant differences in the overall survival rates between the curative and palliative groups at 1 year (100% vs 90%), 3 years (100% vs 52%) and 5 years (100% vs 52%) (P < 0.05). The maximum lung tumour diameter was also a significant prognostic factor. There was local tumour progression in 13 patients (33%) during the mean follow‐up of 25 months. The recurrence‐free survival rates were 92% at 1 year, 23% at 3 years and 23% at 5 years in the curative ablation group. Pneumothorax requiring chest tube placement (six of 89, 7%) and pneumonia (one of 89, 1%) were major complications.
CONCLUSION
Lung RFA is a safe and effective treatment for prolonging survival in patients with unresectable RCC lung metastases.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19338555</pmid><doi>10.1111/j.1464-410X.2009.08459.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-4096 |
| ispartof | BJU international, 2009-09, Vol.104 (6), p.790-794 |
| issn | 1464-4096 1464-410X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67608020 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adult Aged Biological and medical sciences Carcinoma, Renal Cell - mortality Carcinoma, Renal Cell - secondary Carcinoma, Renal Cell - surgery Catheter Ablation - adverse effects Catheter Ablation - methods Diseases of the respiratory system Female Humans Kidney Neoplasms Kidneys lung metastasis Lung Neoplasms - mortality Lung Neoplasms - secondary Lung Neoplasms - surgery Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Palliative Care percutaneous radiofrequency ablation Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) renal cell carcinoma Retrospective Studies Survival Rate Treatment Outcome Tumors of the urinary system |
| title | Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T03%3A25%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Percutaneous%20radiofrequency%20ablation%20for%20unresectable%20pulmonary%20metastases%20from%20renal%20cell%20carcinoma&rft.jtitle=BJU%20international&rft.au=Soga,%20Norihito&rft.date=2009-09&rft.volume=104&rft.issue=6&rft.spage=790&rft.epage=794&rft.pages=790-794&rft.issn=1464-4096&rft.eissn=1464-410X&rft_id=info:doi/10.1111/j.1464-410X.2009.08459.x&rft_dat=%3Cproquest_cross%3E67608020%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4639-7b53f75ba3effd7bbb21a3f2c12abf920d1d51f7bfa867c69352ef27b2ec4a823%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67608020&rft_id=info:pmid/19338555&rfr_iscdi=true |